Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

82.85
+0.09000.11%
Pre-market: 82.80-0.0500-0.06%07:23 EDT
Volume:1.34M
Turnover:111.78M
Market Cap:11.67B
PE:-36.28
High:85.98
Open:83.75
Low:82.36
Close:82.76
52wk High:95.49
52wk Low:28.12
Shares:140.86M
Float Shares:122.00M
Volume Ratio:0.80
T/O Rate:1.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:25.07
PE(LYR):-6,794.88

Loading ...

Arrowhead price target raised to $120 from $115 at H.C. Wainwright

TIPRANKS
·
Aug 07

Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Vera Therapeutics (VERA)

TIPRANKS
·
Aug 05

U.S. Research Roundup-Ametek, Ball Corp, McDonald's

Reuters
·
Aug 05

Arrowhead Pharmaceuticals (ARWR) Gets a Buy from Chardan Capital

TIPRANKS
·
Aug 05

Arrowhead Publishes Transcript of Fiscal 2026 Third-Quarter Conference Call

Reuters
·
Aug 05

Arrowhead Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Arrowhead Pharma Acquires FDA Rare Pediatric Disease Priority Review Voucher

Reuters
·
Aug 05

Earnings Flash (ARWR) Arrowhead Pharmaceuticals Posts Fiscal Q3 Loss $1.36, vs. FactSet Est of $1.28 Loss

MT Newswires Live
·
Aug 05

Arrowhead Pharmaceuticals Q3 Revenue Jumps on Redemplo Growth

Reuters
·
Aug 05

Arrowhead Net Loss Widens to $194.28 Million in FY26 Q3; Revenue Rises to $75.25 Million

Reuters
·
Aug 05

Arrowhead Pharma Q3 EPS $(1.36) Misses $(1.32) Estimate, Sales $75.253M Beat $54.294M Estimate

Benzinga Earnings
·
Aug 05

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

THOMSON REUTERS
·
Aug 05

Arrowhead Pharmaceuticals Q3 EPS USD -1.36

THOMSON REUTERS
·
Aug 05

Arrowhead Pharmaceuticals Q3 Operating Income USD -170.093 Million

THOMSON REUTERS
·
Aug 05

Arrowhead Pharmaceuticals - to Use Voucher for Plozasiran Snda in Severe Hypertriglyceridemia Before End of 2026

THOMSON REUTERS
·
Aug 05

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

THOMSON REUTERS
·
Aug 05

Arrowhead Pharma Grants 112,794 Inducement RSUs to 95 New Hires

Reuters
·
Aug 04

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 04

The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Plozasiran’s Phase 3 Success And Zodasiran Milestone

Simply Wall St.
·
Aug 03

B. Riley Adjusts Arrowhead Pharmaceuticals Price Target to $123 From $101, Maintains Buy Rating

MT Newswires Live
·
Jul 30